Bio

Over his 22-year career, Mr. Robinson has advised many of the most prominent pharmaceutical, biotechnology and medical device companies including Amgen, Biogen Idec, Medtronic, Boston Scientific, Gilead Sciences, Celgene, Vertex, Illumina, PDL, OSI, Onyx, BioMarin, Intermune, Theravance and Resmed. Notable historic landmark transactions include advising: Immunex in its $16 billion sale to Amgen and IDEC in its $7 billion merger with Biogen to create Biogen Idec. Other selected assignments while at Centerview include being the adviser to Pharmacyclics on its $21 billion sale to AbbVie, exclusive advisor to Onyx in its $10.4 billion sale to Amgen, advising Intermune on its $8.9 billion sale to Roche, Receptos on its $7.8bn sale to Celgene, Biogen Idec on the acquisition of strategic and certain financial rights in Tysabri from Elan, Questcor on its $5.6 billion merger with Mallinckrodt, OSI on its hostile defense and $4 billion sale to Astellas, Idenix in its $3.8 billion sale to Merck, Avanir in its $3.5 billion sale to Otsuka and MAP on its sale to Allergan. Prior to Centerview, Mr. Robinson spent 12 years at Merrill Lynch in San Francisco where he had been Global Co-Head of Healthcare Investment Banking for the last six of those years. At the time of his departure from Merrill Lynch, Mr. Robinson had raised more capital for biotechnology companies then anyone in the history of the biotechnology industry. Mr. Robinson joined Merrill Lynch in 1998 to build the biotechnology and medical devices investment banking efforts after working at CS First Boston and Robertson Stephens. Mr. Robinson currently serves on the Board of Trustees of the U.C. Berkeley Foundation and is a member of the Council on Foreign Relations. Mr. Robinson received his B.A. from the University of California Berkeley and an M.B.A. from Harvard Business School.